Physician profile
Jon Strutzenberg
NPI 1174633366
$1,421.65
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $30.36 · 2021: $71.77 · 2022: $271 · 2023: $356 · 2024: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $672.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.64 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $224.44 | 2021-2024 | Farxiga |
| Novo Nordisk INC | $126.08 | 2020-2024 | Ozempic, Rybelsus |
| Allergan, INC. | $122.37 | 2019 | |
| Amgen INC. | $119.48 | 2023-2024 | Repatha, Prolia, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $98.57 | 2022-2023 | |
| Abbvie INC. | $91.93 | 2022-2024 | Vraylar |
| Abbott Laboratories | $51.58 | 2022-2023 | Freestyle Libre 3 |
| Astellas Pharma US INC | $51.14 | 2019-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $46.83 | 2019-2022 | |
| Lilly USA, LLC | $42.08 | 2022-2023 | Mounjaro |
| Pfizer INC. | $31.47 | 2022-2023 | |
| Kowa Pharmaceuticals America, INC. | $31.06 | 2023-2024 | Zoryve, Seglentis |
| Merck Sharp & Dohme LLC | $27.28 | 2019 | |
| Glaxosmithkline, LLC. | $24.30 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $23.80 | 2019 | |
| Exact Sciences Corporation | $23.70 | 2023 | Cologuard Collection Kit |
| Dexcom, INC. | $19.00 | 2023 | Dexcom G6 Transmitter |
| Jazz Pharmaceuticals INC. | $13.68 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.18 | 2022 | |
| Amarin Pharma, INC. | $13.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Strutzenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.